GBGrace Blacker

Grace Blacker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grace Blacker has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SCGB1D2 inhibits growth of Borrelia burgdorferi and affects susceptibility to Lyme disease

    by Satu Strausz, Erik Abner, Grace Blacker, Sarah Galloway, Paige Hansen, Qingying Feng, Brandon T. Lee, Samuel E. Jones, Hele Haapaniemi, Sten Raak, et al.

    Lyme disease is a tick-borne disease caused by bacteria of the genus Borrelia. The host factors that modulate susceptibility for Lyme disease have remained mostly unknown. Using epidemiological and genetic data from FinnGen and Estonian Biobank, we identify two previously known variants and an unknown common missense variant at the gene encoding for Secretoglobin family 1D member 2 (SCGB1D2) protein that increases the susceptibility for Lyme disease. Using live Borrelia burgdorferi (Bb) we find that recombinant reference SCGB1D2 protein inhibits the growth of Bb in vitro more efficiently than the recombinant protein with SCGB1D2 P53L deleterious missense variant. Finally, using an in vivo murine infection model we show that recombinant SCGB1D2 prevents infection by Borrelia in vivo. Together, these data suggest that SCGB1D2 is a host defense factor present in the skin, sweat, and other secretions which protects against Bb infection and opens an exciting therapeutic avenue for Lyme disease.


  • Open Access

    Borrelia burgdorferi modulates the physical forces and immunity signaling in endothelial cells

    by Raúl Aparicio Yuste, Marie Muenkel, Konstantinos Axarlis, María J. Gómez Benito, Annalena Reuss, Grace Blacker, Michal Caspi Tal, Peter Kraiczy, Effie E. Bastounis


  • CD47 Blockade Leads to Chemokine-Dependent Monocyte Infiltration and Loss of B Cells from the Splenic Marginal Zone

    by Ying Ying Yiu, Paige S. Hansen, Laughing Bear Torrez Dulgeroff, Grace Blacker, Lara Myers, Sarah Galloway, Eric Gars, Olivia Colace, Paul Mansfield, Kim J. Hasenkrug, et al.

    CD47 is an important innate immune checkpoint through its interaction with its inhibitory receptor on macrophages, signal-regulatory protein α (SIRPα). Therapeutic blockade of CD47–SIRPα interactions is a promising immuno-oncology treatment that promotes clearance of cancer cells. However, CD47–SIRPα interactions also maintain homeostatic lymphocyte levels. In this study, we report that the mouse splenic marginal zone B cell population is dependent on intact CD47–SIRPα interactions and blockade of CD47 leads to the loss of these cells. This depletion is accompanied by elevated levels of monocyte-recruiting chemokines CCL2 and CCL7 and infiltration of CCR2+Ly6Chi monocytes into the mouse spleen. In the absence of CCR2 signaling, there is no infiltration and reduced marginal zone B cell depletion. These data suggest that CD47 blockade leads to clearance of splenic marginal zone B cells. Key Points CD47 blockade leads to rapid but resolvable splenic marginal zone B cell depletion. Anti-CD47 mAb induced CCL2/CCL7 is accompanied by CCR2+ monocyte splenic infiltration.